Aptorum Group Limited (NASDAQ:APM) Short Interest Down 24.8% in March

Aptorum Group Limited (NASDAQ:APM) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 8,693 shares, a decline of 24.8% from the February 26th total of 11,553 shares. Based on an average daily trading volume, of 21,427 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.4% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Aptorum Group Price Performance

APM opened at $0.84 on Tuesday. The stock has a fifty day moving average price of $0.87 and a 200 day moving average price of $1.25. Aptorum Group has a 1 year low of $0.65 and a 1 year high of $4.47.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.